Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease

The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group （hemoglobin of 13 g/dl）and low-hemoglobin target group （hemoglobin of 11 g/dl）and administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.

NCT Number	NCT06725810
Lead Sponsor	Shanghai Zhongshan Hospital
Conditions	Chronic Kidney Disease Associated Anemia
Enrollment	1,670 participants
Start Date	2025-03-27
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-28